Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2023-06-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
关于全资子公司参与投资基金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Changchun High-tech Industry (Group) Co., Ltd. regarding its wholly-owned subsidiary's participation in an investment fund. It details the investment agreement, fund information, management, investment scope, and risk factors. The document is a formal disclosure about a capital investment activity, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but rather informs shareholders and the market about a financing/investment update. The document length is 4319 characters, which is relatively short and focused on a specific capital investment event. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-06-27 Chinese
关于市场传闻的情况说明及风险提示公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the company's board addressing recent market rumors and stock price volatility related to a policy (Zhejiang集采). It clarifies that no material undisclosed information exists and reminds investors to rely on official disclosures. The document is short (1309 characters) and primarily serves to clarify and update investors on the company's position regarding market rumors and information disclosure compliance. It does not contain financial statements, detailed financial data, or comprehensive report content. It is an official regulatory announcement to the market about information disclosure and stock price movements, fitting the category of a Regulatory Filing (RNS).
2023-06-11 Chinese
关于2022年限制性股票与股票期权激励计划部分限制性股票注销完成暨不调整定向可转债转股价格的公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement from Changchun High-tech Industry (Group) Co., Ltd. regarding the repurchase and cancellation of part of its 2022 restricted stock and stock option incentive plan. It includes specifics about the number of shares repurchased, the reasons for repurchase, approvals from board and shareholders meetings, changes in share capital, and the impact on convertible bond conversion price. The document is a formal announcement of a share repurchase and cancellation event related to stock incentives, with detailed procedural and financial information. It is not a full financial report, earnings release, or management discussion, nor is it a regulatory filing or proxy solicitation. The content fits best under the category of Transaction in Own Shares (POS), which covers company buybacks or sales of its own shares.
2023-05-29 Chinese
关于控股子公司注射用金纳单抗临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Changchun High & New Technology Industries (Group) Co., Ltd. regarding the approval of a clinical trial application for a drug by its controlling subsidiary. It includes details about the drug, regulatory approval from the National Medical Products Administration, and a cautionary note about investment risks. There is no financial data, no mention of financial results, no report attached or referenced, and no indication of a meeting or voting results. The document is a regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2023-05-25 Chinese
关于控股子公司醋酸曲普瑞林注射液补充申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Changchun High-tech Industry Group Co., Ltd. regarding the approval of a supplementary application for a drug product by its controlling subsidiary. It details regulatory approval from the National Medical Products Administration for changes in drug formulation, production process, quality standards, packaging, and instructions. The document includes a risk warning for investors about market uncertainties. There is no financial data, no mention of financial results, no shareholder voting, no management changes, no earnings, no capital updates, and no legal proceedings. The document is a regulatory announcement about product approval and related information. It is short (976 characters) and serves as a formal disclosure to investors about regulatory approval and risks. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-05-19 Chinese
关于参加网上集体业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the company's participation in an online collective earnings explanation meeting organized by regulatory and industry bodies. It includes details about the event date, time, platform, and participating company executives who will interact with investors. The document does not contain actual financial statements or detailed financial analysis but rather informs about an upcoming investor presentation event focused on discussing company performance. Therefore, it fits the category of an Investor Presentation (IP) announcement rather than a full report or earnings release.
2023-05-12 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.